{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T17:19:31.831109+00:00","company":{"ticker":"NKTX","cik":1787400,"company_name":"Nkarta, Inc."},"pagination":{"limit":100,"returned":28,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{},"facts":[{"fact_type":"shareholder_vote","fact_key":"72ad838ba869341070bed2d33a91cb482598e533","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2026-06-11T20:59:06+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":"6,934,994","subject":null,"votes_abstain":"354,355","votes_against":null,"votes_for":"34,447,256","votes_withheld":null}]},"claim":"Nkarta, Inc. shareholders approved Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation at the 2026-06-10 meeting.","evidence_excerpt":"The stockholders voted, on a non-binding, advisory basis, on the frequency of future advisory votes on the compensation paid to the Company’s named executive officers. The voting results were as follows: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 34,447,256 21,461 4,565,940 354,355 6,934,994","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-267830","anchor_url":"https://secwatch.observer/filing/0001193125-26-267830#claim-72ad838ba869341070bed2d33a91cb482598e533","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000119312526267830/0001193125-26-267830-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3a99fa470ebdd6e1960c7ece025ca66a5cea5566","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2026-06-11T20:59:06+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Advisory Approval of the Compensation Paid to the Company’s Named Executive Officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"6,934,994","subject":null,"votes_abstain":"38,722","votes_against":"3,313,424","votes_for":"43,493,065","votes_withheld":null}]},"claim":"Nkarta, Inc. shareholders approved Advisory Approval of the Compensation Paid to the Company’s Named Executive Officers at the 2026-06-10 meeting.","evidence_excerpt":"The stockholders approved, on a non- binding, advisory basis, the compensation paid to the Company’s named executive officers. The voting results were as follows: For Against Abstain Broker Non-Votes 43,493,065 3,313,424 38,722 6,934,994","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-267830","anchor_url":"https://secwatch.observer/filing/0001193125-26-267830#claim-3a99fa470ebdd6e1960c7ece025ca66a5cea5566","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000119312526267830/0001193125-26-267830-index.htm"},{"fact_type":"shareholder_vote","fact_key":"84da1266a69ba6bd568e0868811325a41674b991","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2026-06-11T20:59:06+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Ratification of Appointment of Ernst & Young LLP","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"19,780","votes_against":"76,073","votes_for":"53,684,352","votes_withheld":null}]},"claim":"Nkarta, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP at the 2026-06-10 meeting.","evidence_excerpt":"The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The voting results were as follows: For Against Abstain Broker Non-Votes 53,684,352 76,073 19,780 —","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-267830","anchor_url":"https://secwatch.observer/filing/0001193125-26-267830#claim-84da1266a69ba6bd568e0868811325a41674b991","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000119312526267830/0001193125-26-267830-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3666babd4370981438344bf241f939a46fdd7693","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2026-06-11T20:59:06+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Election of Class III directors","proposal_type":"director_election","results":[{"broker_non_votes":"6,934,994","subject":"Ali Behbahani, M.D., M.B.A.","votes_abstain":null,"votes_against":null,"votes_for":"32,285,680","votes_withheld":"14,559,531"},{"broker_non_votes":"6,934,994","subject":"Zachary Scheiner, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"37,313,469","votes_withheld":"9,531,742"}]},"claim":"Nkarta, Inc. shareholders approved Election of Class III directors at the 2026-06-10 meeting.","evidence_excerpt":"The stockholders elected the following two Class III directors to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified. The voting results were as follows: For Withheld Broker Non-Votes Ali Behbahani, M.D., M.B.A. 32,285,680 14,559,531 6,934,994 Zachary Scheiner, Ph.D. 37,313,469 9,531,742 6,934,994","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-267830","anchor_url":"https://secwatch.observer/filing/0001193125-26-267830#claim-3666babd4370981438344bf241f939a46fdd7693","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000119312526267830/0001193125-26-267830-index.htm"},{"fact_type":"earnings_release","fact_key":"65826f6805c06592a7a052da2a49781546cd25c0","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2026-05-12T20:04:35+00:00","payload":{"eps_text":"$0.37 per basic and diluted share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$27.8 million, or $0.37 per basic and diluted share","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-12","result_type":"reported_results","revenue_text":null},"claim":"Nkarta, Inc. reported first quarter ended March 31, 2026 results: net income $27.8 million, or $0.37 per basic and diluted share, EPS $0.37 per basic and diluted share. Guidance reaffirmed.","evidence_excerpt":"Nkarta, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001787400-26-000012","anchor_url":"https://secwatch.observer/filing/0001787400-26-000012#claim-65826f6805c06592a7a052da2a49781546cd25c0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000178740026000012/0001787400-26-000012-index.htm"},{"fact_type":"earnings_release","fact_key":"8be35e55366a6a19205bfea7af7ab0b72d357cfb","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2026-03-25T23:59:59+00:00","payload":{"eps_text":"$1.41 per basic and diluted share (full year); $0.37 per basic and diluted share (fourth quarter)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $104.1 million, or $1.41 per basic and diluted share, for the full year 2025. Net loss was $27.4 million, o","period_text":"the fourth quarter and year ended December 31, 2025","report_date":"2026-03-25","result_type":"reported_results","revenue_text":null},"claim":"Nkarta, Inc. reported the fourth quarter and year ended December 31, 2025 results: net income Net loss was $104.1 million, or $1.41 per basic and diluted share, for the full year 2025. Net loss was $27.4 million, o, EPS $1.41 per basic and diluted share (full year); $0.37 per basic and diluted share (fourth quarter).","evidence_excerpt":"On March 25, 2026, Nkarta, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001787400-26-000005","anchor_url":"https://secwatch.observer/filing/0001787400-26-000005#claim-8be35e55366a6a19205bfea7af7ab0b72d357cfb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000178740026000005/0001787400-26-000005-index.htm"},{"fact_type":"executive_change","fact_key":"615288b124","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2025-06-06T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-23","interim":false,"role":"Chief Medical Officer and Head of Research and Development","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Shawn Rose was appointed as Chief Medical Officer and Head of Research and Development at Nkarta, Inc..","evidence_excerpt":"Shawn Rose, M.D. Ph.D. has been appointed by the Company to succeed Dr. Shook as Chief Medical Officer and Head of Research and Development starting on June 23, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-082717","anchor_url":"https://secwatch.observer/filing/0000950170-25-082717#claim-615288b124","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017025082717/0000950170-25-082717-index.htm"},{"fact_type":"executive_change","fact_key":"50dac225ce","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2025-06-06T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-06-06","interim":false,"role":"Chief Medical Officer and Head of Research & Development","role_category":"other_named_officer","successor_name":"Shawn Rose, M.D. Ph.D.","successor_named":true},"claim":"David Shook resigned as Chief Medical Officer and Head of Research & Development at Nkarta, Inc..","evidence_excerpt":"David Shook, M.D. notified Nkarta, Inc. (the “Company”) of his decision to resign as Chief Medical Officer and Head of Research & Development of the Company to pursue other opportunities in the oncology space.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-082717","anchor_url":"https://secwatch.observer/filing/0000950170-25-082717#claim-50dac225ce","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017025082717/0000950170-25-082717-index.htm"},{"fact_type":"restructuring_charge","fact_key":"8ddc32d09a408e443793322842ae204db746db2f","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2025-03-26T23:59:59+00:00","payload":{"affected_area":null,"charge_text":"approximately $5.5 million to $6.5 million","effective_date":"2025-03-26","event_type":"restructuring","headcount_text":"approximately 34% of the Company’s workforce, or 53 positions","item_codes_triggered":["2.05"]},"claim":"Nkarta, Inc. announced a restructuring with charges of approximately $5.5 million to $6.5 million (approximately 34% of the Company’s workforce, or 53 positions).","evidence_excerpt":"are expected to extend the Company’s cash runway into 2029. In connection with the implementation of the Reduction, the Company currently estimates it will incur approximately $5.5 million to $6.5 million in expenses, consisting primarily of cash severance costs, benefits, payroll taxes and other termination costs for impacted employees, which the Company expects","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-045231","anchor_url":"https://secwatch.observer/filing/0000950170-25-045231#claim-8ddc32d09a408e443793322842ae204db746db2f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017025045231/0000950170-25-045231-index.htm"},{"fact_type":"executive_change","fact_key":"00c4b5d8a4","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2025-03-26T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-03-31","interim":false,"role":"principal financial officer and principal accounting officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Nadir Mahmood was appointed as principal financial officer and principal accounting officer at Nkarta, Inc..","evidence_excerpt":"Effective as of Levin Transition Date, the Board appointed Nadir Mahmood, Ph.D., the Company’s President, to succeed Ms. Levin as the Company’s principal financial officer and principal accounting officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-045231","anchor_url":"https://secwatch.observer/filing/0000950170-25-045231#claim-00c4b5d8a4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017025045231/0000950170-25-045231-index.htm"},{"fact_type":"executive_change","fact_key":"2d68db2cbb","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2025-03-26T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"routine","effective_date":"2025-03-31","interim":false,"role":"Chief Financial and Business Officer","role_category":"cfo","successor_name":"Nadir Mahmood","successor_named":true},"claim":"Alyssa Levin was terminated as Chief Financial and Business Officer at Nkarta, Inc..","evidence_excerpt":"On March 26, 2025, the Company announced that Alyssa Levin’s employment would be terminated effective March 31, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-045231","anchor_url":"https://secwatch.observer/filing/0000950170-25-045231#claim-2d68db2cbb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017025045231/0000950170-25-045231-index.htm"},{"fact_type":"executive_change","fact_key":"1844167f50","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2024-07-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-07-29","interim":false,"role":"President","role_category":"president","successor_name":null,"successor_named":false},"claim":"Nadir Mahmood was appointed as President at Nkarta, Inc..","evidence_excerpt":"On July 10, 2024, Nkarta, Inc.'s (the “Company”) Board of Directors (the “Board”) appointed Nadir Mahmood, Ph.D. as the Company’s President, effective July 29, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-24-083761","anchor_url":"https://secwatch.observer/filing/0000950170-24-083761#claim-1844167f50","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024083761/0000950170-24-083761-index.htm"},{"fact_type":"earnings_release","fact_key":"1bd772e015324e8a6d89307bc5de93bb04512928","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":"$0.58 per basic and diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $29.5 million, or $0.58 per basic and diluted share, for the first quarter of 2024.","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":null},"claim":"Nkarta, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $29.5 million, or $0.58 per basic and diluted share, for the first quarter of 2024., EPS $0.58 per basic and diluted share.","evidence_excerpt":"Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter ended March 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-056870","anchor_url":"https://secwatch.observer/filing/0000950170-24-056870#claim-1bd772e015324e8a6d89307bc5de93bb04512928","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024056870/0000950170-24-056870-index.htm"},{"fact_type":"earnings_release","fact_key":"9f9f03a6de3f57c2a3e488c018e8bcb7d365eda0","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2024-03-21T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and year ended December 31, 2023","report_date":"2024-03-21","result_type":"reported_results","revenue_text":null},"claim":"Nkarta, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On March 21, 2024, Nkarta, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-034710","anchor_url":"https://secwatch.observer/filing/0000950170-24-034710#claim-9f9f03a6de3f57c2a3e488c018e8bcb7d365eda0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024034710/0000950170-24-034710-index.htm"},{"fact_type":"earnings_release","fact_key":"1d39c2f26295015b93643e8870d173e201f809bc","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2023-11-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the third quarter ended September 30, 2023","report_date":"2023-11-09","result_type":"reported_results","revenue_text":null},"claim":"Nkarta, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, Nkarta, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-062019","anchor_url":"https://secwatch.observer/filing/0000950170-23-062019#claim-1d39c2f26295015b93643e8870d173e201f809bc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023062019/0000950170-23-062019-index.htm"},{"fact_type":"restructuring_charge","fact_key":"a71f76a72428154e7f4507651f4d27e85907fc80","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2023-10-17T23:59:59+00:00","payload":{"affected_area":"Reduction in force of 18 positions, representing approximately 10% of the Company's workforce","charge_text":"approximately $1 million to $1.5 million","effective_date":"2023-10-16","event_type":"restructuring","headcount_text":"reduction of 18 positions","item_codes_triggered":["2.05"]},"claim":"Nkarta, Inc. announced a restructuring with charges of approximately $1 million to $1.5 million affecting Reduction in force of 18 positions, representing approximately 10% of the Company's workforce (reduction of 18 positions).","evidence_excerpt":"to extend the Company’s cash runway by one year into 2026. In connection with the implementation of the Reduction, the Company currently estimates it will incur approximately $1 million to $1.5 million in costs, consisting primarily of cash severance costs and transition support services for impacted employees, which the Company expects to recognize in the","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-053645","anchor_url":"https://secwatch.observer/filing/0000950170-23-053645#claim-a71f76a72428154e7f4507651f4d27e85907fc80","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023053645/0000950170-23-053645-index.htm"},{"fact_type":"earnings_release","fact_key":"754743a18f063761a4156a0d37f58fd8b8c452d7","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2023-08-10T23:59:59+00:00","payload":{"eps_text":"$0.68 per basic and diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $33.3 million, or $0.68 per basic and diluted share","period_text":"second quarter ended June 30, 2023","report_date":"2023-08-10","result_type":"reported_results","revenue_text":null},"claim":"Nkarta, Inc. reported second quarter ended June 30, 2023 results: net income Net loss was $33.3 million, or $0.68 per basic and diluted share, EPS $0.68 per basic and diluted share.","evidence_excerpt":"Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-040948","anchor_url":"https://secwatch.observer/filing/0000950170-23-040948#claim-754743a18f063761a4156a0d37f58fd8b8c452d7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023040948/0000950170-23-040948-index.htm"},{"fact_type":"executive_change","fact_key":"fdf322c658","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2023-07-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-07-01","interim":false,"role":"Chief Financial and Business Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Alyssa Levin was appointed as Chief Financial and Business Officer at Nkarta, Inc..","evidence_excerpt":"On June 29, 2023, Nkarta, Inc.'s (the “Company”) Board of Directors (the “Board”) appointed Alyssa Levin as the Company’s Chief Financial and Business Officer and the principal financial and accounting officer, effective July 1, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-031624","anchor_url":"https://secwatch.observer/filing/0000950170-23-031624#claim-fdf322c658","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023031624/0000950170-23-031624-index.htm"},{"fact_type":"governance_change","fact_key":"bc815cdb7d9f3370547795e8a21bc99045a60526","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2023-06-09T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-06-07","item_codes_triggered":["5.03"],"summary_text":"Stockholders approved an amendment to the Certificate of Incorporation to provide for exculpation of officers."},"claim":"Nkarta, Inc.: Stockholders approved an amendment to the Certificate of Incorporation to provide for exculpation of officers (effective 2023-06-07).","evidence_excerpt":"The 2023 annual meeting of stockholders (the “Annual Meeting”) of Nkarta, Inc. (the “Company”) was held on June 7, 2023, at which stockholders approved an amendment (the “Amendment”) to the Company’s Restated Certificate of Incorporation to provide for exculpation of officers as permitted by the Delaware General Corporation Law. The Amendment became effective immediately upon filing with the Secretary of State of the State of Delaware on June 7, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-027263","anchor_url":"https://secwatch.observer/filing/0000950170-23-027263#claim-bc815cdb7d9f3370547795e8a21bc99045a60526","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023027263/0000950170-23-027263-index.htm"},{"fact_type":"shareholder_vote","fact_key":"42818bc95846ab931b4dd3d3c64fbdb160803b41","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2023-06-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approval of amendment to the Company's Certificate of Incorporation to provide for exculpation of officers as permitted by the Delaware General Corporation Law","proposal_type":"charter_amendment","results":[{"broker_non_votes":"3,405,710","subject":null,"votes_abstain":"8,594","votes_against":"1,113,073","votes_for":"38,837,270","votes_withheld":null}]},"claim":"Nkarta, Inc. shareholders approved Approval of amendment to the Company's Certificate of Incorporation to provide for exculpation of officers as permitted by the Delaware General Corporation Law.","evidence_excerpt":"The stockholders approved the amendment of the Company's Certificate of Incorporation to provide for exculpation of officers as permitted by the Delaware General Corporation .","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-027263","anchor_url":"https://secwatch.observer/filing/0000950170-23-027263#claim-42818bc95846ab931b4dd3d3c64fbdb160803b41","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023027263/0000950170-23-027263-index.htm"},{"fact_type":"shareholder_vote","fact_key":"288caade8743df92ffd79cbf2a9d9c60104090cb","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2023-06-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-31","outcome":"passed","proposal_text":"Ratification of Appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"3,079","votes_against":"6,927","votes_for":"43,354,641","votes_withheld":null}]},"claim":"Nkarta, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-12-31 meeting.","evidence_excerpt":"The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-027263","anchor_url":"https://secwatch.observer/filing/0000950170-23-027263#claim-288caade8743df92ffd79cbf2a9d9c60104090cb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023027263/0000950170-23-027263-index.htm"},{"fact_type":"shareholder_vote","fact_key":"974a996c6d3bd3c34050f4d87cdcd74e05b0a151","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2023-06-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Election of Class III directors to serve until the Company's 2026 annual meeting of stockholders and until their respective successors are duly elected and qualified","proposal_type":"director_election","results":[{"broker_non_votes":"3,405,710","subject":"Ali Behbahani, M.D., M.B.A.","votes_abstain":null,"votes_against":null,"votes_for":"27,251,721","votes_withheld":"12,707,216"},{"broker_non_votes":"3,405,710","subject":"Zachary Scheiner, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"37,487,361","votes_withheld":"2,471,576"}]},"claim":"Nkarta, Inc. shareholders approved Election of Class III directors to serve until the Company's 2026 annual meeting of stockholders and until their respective successors are duly elected and qualified.","evidence_excerpt":"The stockholders elected the following three Class III directors to serve until the Company’s 2026 annual meeting of stockholders and until their respective successors are duly elected and qualified.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-027263","anchor_url":"https://secwatch.observer/filing/0000950170-23-027263#claim-974a996c6d3bd3c34050f4d87cdcd74e05b0a151","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023027263/0000950170-23-027263-index.htm"},{"fact_type":"earnings_release","fact_key":"94c9bfdbd1bf7f8e27624a74e5b12da277b3ce5d","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2023-05-11T23:59:59+00:00","payload":{"eps_text":"$0.63 per basic and diluted share","guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":"$30.8 million","period_text":"for the first quarter ended March 31, 2023","report_date":"2023-05-11","result_type":"reported_results","revenue_text":null},"claim":"Nkarta, Inc. reported for the first quarter ended March 31, 2023 results: net income $30.8 million, EPS $0.63 per basic and diluted share. Guidance initiated.","evidence_excerpt":"Net loss was $30.8 million, or $0.63 per basic and diluted share, for the first quarter of 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-021218","anchor_url":"https://secwatch.observer/filing/0000950170-23-021218#claim-94c9bfdbd1bf7f8e27624a74e5b12da277b3ce5d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023021218/0000950170-23-021218-index.htm"},{"fact_type":"executive_change","fact_key":"3bbf22f9d0","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2023-03-30T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-06-30","interim":false,"role":"Chief Financial and Business Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Nadir Mahmood resigned as Chief Financial and Business Officer at Nkarta, Inc..","evidence_excerpt":"Dr. Nadir Mahmood notified Nkarta, Inc. (the “Company”) of his decision to resign as Chief Financial and Business Officer of the Company to take a position as chief executive officer of a private biotechnology company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-010937","anchor_url":"https://secwatch.observer/filing/0000950170-23-010937#claim-3bbf22f9d0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023010937/0000950170-23-010937-index.htm"},{"fact_type":"earnings_release","fact_key":"340687bc93227d408bfe39227f01c0cb79c94789","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2022-11-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the third quarter ended September 30, 2022","report_date":"2022-11-09","result_type":"reported_results","revenue_text":null},"claim":"Nkarta, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 9, 2022, Nkarta, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2022.","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0000950170-22-023827","anchor_url":"https://secwatch.observer/filing/0000950170-22-023827#claim-340687bc93227d408bfe39227f01c0cb79c94789","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022023827/0000950170-22-023827-index.htm"},{"fact_type":"executive_change","fact_key":"a5b66f7d97","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2022-05-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Vice President, Clinical Development","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Dr. David Shook was appointed as Vice President, Clinical Development at Nkarta, Inc..","evidence_excerpt":"On May 16, 2022, the Company issued a press release announcing the resignation of Dr. Rajangam and the appointment of Dr. David Shook as Vice President, Clinical Development.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-22-010075","anchor_url":"https://secwatch.observer/filing/0000950170-22-010075#claim-a5b66f7d97","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022010075/0000950170-22-010075-index.htm"},{"fact_type":"executive_change","fact_key":"dfdcb22991","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2022-05-16T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-06-05","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Dr. Kanya Rajangam resigned as Chief Medical Officer at Nkarta, Inc..","evidence_excerpt":"On May 13, 2022, Dr. Kanya Rajangam notified Nkarta, Inc. (the “Company”) of her decision to resign as Chief Medical Officer of the Company to oversee research and development activities at a private biotechnology company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-22-010075","anchor_url":"https://secwatch.observer/filing/0000950170-22-010075#claim-dfdcb22991","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022010075/0000950170-22-010075-index.htm"},{"fact_type":"executive_change","fact_key":"e4c550c7ba","cik":1787400,"ticker":"NKTX","company_name":"Nkarta, Inc.","filed_at":"2022-03-29T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-03-28","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Angela Thedinga was appointed as Director at Nkarta, Inc..","evidence_excerpt":"On March 28, 2022, the Board of Directors (the \"Board\") of Nkarta, Inc. (the \"Company\"), on the recommendation of the Nominating and Governance Committee of the Board, increased the size of the Board from nine directors to ten directors and appointed Angela Thedinga to the Board effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-22-004854","anchor_url":"https://secwatch.observer/filing/0000950170-22-004854#claim-e4c550c7ba","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022004854/0000950170-22-004854-index.htm"}]}